Finance

Lists
KNSA:NASDAQ
Kiniksa Pharmaceuticals Internatinl, PLC
US$96.33
+0.05%
(+0.050) 1D
ኖቬም 13, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KNSA...
Open
US$96.37
High
US$96.75
Low
US$94.50
Mkt. cap
7.57 ቢ
Avg. vol.
819.14 ሺ
Volume
465.63 ሺ
P/E ratio
73.53
52-wk high
US$99.31
52-wk low
US$37.02
EPS
US$1.31
Beta
0.07
Shares outstanding
48.84 ሚ
No. of employees
366
Open
US$96.37
High
US$96.75
Low
US$94.50
Mkt. cap
7.57 ቢ
Avg. vol.
819.14 ሺ
Volume
465.63 ሺ
P/E ratio
73.53
52-wk high
US$99.31
52-wk low
US$37.02
EPS
US$1.31
Beta
0.07
Shares outstanding
48.84 ሚ
No. of employees
366
News stories
From web sources and news partners
About Kiniksa Pharmaceuticals Internatinl, PLC
CEO-
Employees366
Founded2015
Headquartersለንደን, ኢንግላንድ, እንግሊዝ
SectorHealth Care
IndustryBiotechnology
Websitekiniksa.com
Analyst ratings
Based on 5 analysts giving stock ratings to KNSA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KNSA in the last 3 months.
Highest
Current US$96.33
US$122.00 (+26.65%)
Average
US$106.20 (+10.25%)
Lowest
US$98.00 (+1.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Reiterated
US$122.00
+26.6%
10/30/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
US$98.00
+1.7%
10/28/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
US$110.00
+14.2%
10/28/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
US$101.00
+4.8%
10/27/2026
Geoff Meacham
Citi
Buy
Maintained
US$100.00
+3.8%
10/15/2026
David Nierengarten
Wedbush
Buy
Reiterated
US$99.00
+2.8%
07/28/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
US$87.00
-9.7%
07/29/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
US$95.00
-1.4%
07/28/2026
Roger Song
Jefferies
Buy
Maintained
US$71.00
-26.3%
04/28/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
US$53.00
-45%
04/14/2026
Last report
27 ኦክቶ 2026
Fiscal period
Q3 2026
US$0.56 / US$0.31
+79.20%beat
Revenue / Est. (USD)
285.97 ሚ / 260.61 ሚ
+9.73%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
202.13 ሚ
214.27 ሚ
243.60 ሚ
285.97 ሚ
Cost of goods sold
90.98 ሚ
96.37 ሚ
111.64 ሚ
133.59 ሚ
Cost of revenue
90.98 ሚ
96.37 ሚ
111.64 ሚ
133.59 ሚ
Research and development expenses
34.61 ሚ
27.48 ሚ
40.90 ሚ
32.79 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
56.78 ሚ
61.15 ሚ
63.87 ሚ
65.36 ሚ
Operating expense
91.38 ሚ
88.63 ሚ
104.76 ሚ
98.15 ሚ
Total operating expenses
182.36 ሚ
185.00 ሚ
216.41 ሚ
231.73 ሚ
Operating income
19.77 ሚ
29.27 ሚ
27.19 ሚ
54.24 ሚ
Other non operating income
3.50 ሚ
3.41 ሚ
3.95 ሚ
-169.00 ሺ
EBT including unusual items
23.27 ሚ
32.68 ሚ
31.14 ሚ
59.06 ሚ
EBT excluding unusual items
23.27 ሚ
32.68 ሚ
31.14 ሚ
59.06 ሚ
Income tax expense
9.07 ሚ
10.09 ሚ
5.71 ሚ
11.71 ሚ
Effective tax rate
38.98%
30.87%
18.34%
19.83%
Other operating expenses
-
-
-
-
Net income
14.20 ሚ
22.59 ሚ
25.43 ሚ
47.34 ሚ
Net profit margin
7.02%
10.54%
10.44%
16.56%
Earnings per share
0.17
0.27
0.30
0.56
Interest and investment income
-
-
-
4.99 ሚ
Interest expense
-
-
-
-
Net interest expenses
-
-
-
4.99 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
20.24 ሚ
29.74 ሚ
27.67 ሚ
54.73 ሚ
Gain or loss from assets sale
-53.00 ሺ
-54.00 ሺ
22.00 ሺ
8.00 ሺ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች